SAB Biotherapeutics, Inc. (NASDAQ:SABS) Short Interest Down 42.8% in February

SAB Biotherapeutics, Inc. (NASDAQ:SABS) saw a large decrease in short interest in February. As of February 15th, there was short interest totalling 67,700 shares, a decrease of 42.8% from the January 31st total of 118,400 shares. Based on an average daily trading volume, of 127,400 shares, the days-to-cover ratio is currently 0.5 days. Currently, 0.9% of the company’s shares are sold short.

SAB Biotherapeutics Trading Down 1.9 %

Shares of SAB Biotherapeutics stock traded down $0.03 during trading hours on Tuesday, hitting $1.53. The company’s stock had a trading volume of 7,457 shares, compared to its average volume of 148,850. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.69 and a current ratio of 3.69. SAB Biotherapeutics has a twelve month low of $1.53 and a twelve month high of $6.30. The firm has a fifty day moving average of $2.87 and a 200-day moving average of $3.00.

Wall Street Analysts Forecast Growth

SABS has been the topic of several analyst reports. HC Wainwright reiterated a “buy” rating and set a $6.00 price target on shares of SAB Biotherapeutics in a report on Wednesday, January 29th. Chardan Capital reiterated a “buy” rating and issued a $25.00 target price on shares of SAB Biotherapeutics in a report on Wednesday, January 29th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $12.40.

Institutional Trading of SAB Biotherapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Northern Trust Corp acquired a new stake in shares of SAB Biotherapeutics during the fourth quarter valued at about $43,000. Diadema Partners LP purchased a new position in shares of SAB Biotherapeutics during the 4th quarter worth approximately $114,000. Geode Capital Management LLC increased its holdings in SAB Biotherapeutics by 18.8% in the 4th quarter. Geode Capital Management LLC now owns 80,234 shares of the company’s stock valued at $307,000 after purchasing an additional 12,692 shares during the last quarter. HB Wealth Management LLC raised its position in SAB Biotherapeutics by 118.6% in the fourth quarter. HB Wealth Management LLC now owns 237,400 shares of the company’s stock valued at $982,000 after purchasing an additional 128,800 shares during the period. Finally, Kovitz Investment Group Partners LLC acquired a new position in SAB Biotherapeutics during the third quarter worth $52,000. 7.82% of the stock is currently owned by hedge funds and other institutional investors.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.